Warfarin Monitoring Woes: A Glimmer of Hope with Pharmacogenomics

Journal of the American Medical Directors Association

Volumn 9, Issue 3, 2008, Pages 199-200

  Beier, Manju T ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DIGOXIN; GINGER EXTRACT; HYPERICUM PERFORATUM EXTRACT; INSULIN; UBIDECARENONE; WARFARIN;

ALTERNATIVE MEDICINE; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLEEDING TENDENCY; DRUG DOSE REGIMEN; DRUG LABELING; DRUG METABOLISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG SURVEILLANCE PROGRAM; EVIDENCE BASED MEDICINE; GENETIC ANALYSIS; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HUMAN; INDIVIDUALIZATION; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; MEDICAL DECISION MAKING; NURSING HOME; OPTIMAL DRUG DOSE; PHARMACOGENOMICS; PRACTICE GUIDELINE; PRESCRIPTION; STROKE; TREATMENT PLANNING;

EID: 39149086090     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2007.12.007     Document Type: Article

References (8)

1. McCormick D., Gurwitz J.H., Goldberg R.J., et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med 161 (2001) 2458-2463
2. Gurwitz J.H., Field T.S., Radford M.J., et al. The safety of warfarin therapy in the nursing home setting. Am J Med 120 (2007) 539-544
3. Budnitz D.S., Shehab N., Kegler S.R., and Richards C.L. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 147 (2007) 755-765
4. Beier M.T. Warfarin monitoring: consider the three Ds. J Am Med Dir Assoc 6 (2005) 76
5. Shalansky S., Lynd L., Richardson K., Ingaszewski A., and Kerr C. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. Pharmacotherapy 27 (2007) 1237-1247
6. Food and Drug Administration. New Labeling Information for Warfarin (2007). http://www.fda.gov/cder/drug/infopage/warfarin/default.htm Available at: http://www.fda.gov/cder/drug/infopage/warfarin/default.htm. Accessed December 7
7. Food and Drug Administration. FDA Clears Genetic Lab Test for Warfarin Sensitivity (2007). http://www.fda.gov/bbs/topics/NEWS/2007/NEW01701.html Available at: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01701.html. Accessed December 7
8. Food and Drug Administration. FDA's Critical Path Initiative: Warfarin Dosing (2007). http://www.fda.gov/oc/initiatives/criticalpath/warfarin.html Available at: http://www.fda.gov/oc/initiatives/criticalpath/warfarin.html. Accessed December 7